June 3, 2026 | Endpoints News
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
June 3, 2026 | Fierce Biotech
Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases
June 3, 2026 | Genetic Engineering & Biotechnology News
Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases
June 3, 2026 | Pharmaceutical Executive
Ascidian and Eli Lilly Enter $1.9 Billion Global Research Collaboration to Develop RNA Exon Editors
June 3, 2026 | Reuters
Lilly gains license for Ascidian’s gene-editing tech to develop kidney disease drugs
June 3, 2026 | The Wall Street Journal
Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
January 13, 2026 | INFORMA